Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14C-bleximenib
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bleximenib (JNJ-75276617) is an investigational, orally bioavailable small molecule inhibitor of the menin-KMT2A (lysine methyltransferase 2A) protein-protein interaction, developed by Janssen Research & Development. It is specifically designed for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) harboring KMT2A rearrangements or NPM1 mutations. By binding to menin, the drug prevents its association with KMT2A, leading to the downregulation of critical leukemogenic drivers such as HOXA9 and MEIS1. The 14C-labeled version (14C-bleximenib) is a radiolabeled formulation used in Phase 1 clinical trials to conduct absorption, metabolism, and excretion (AME) studies, allowing researchers to track the drug's metabolic pathways and mass balance in human subjects.
- Other names
- radiolabeled bleximenib[14C]bleximenib14C-labeled bleximenib
02
Targets
Menin – KMT2A interaction site on menin
Beyond the preview
Go deeper on 14C-bleximenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 14C-bleximenib.